Luca Cantarini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5913947/publications.pdf

Version: 2024-02-01

395 papers	13,075 citations	25014 57 h-index	42364 92 g-index
402 all docs	402 docs citations	402 times ranked	10280 citing authors

#	Article	IF	Citations
1	Pediatric Scleritis: An Update. Ocular Immunology and Inflammation, 2023, 31, 175-184.	1.0	4
2	Diffuse Peripheral Enthesitis in Metabolic Syndrome: A Retrospective Clinical and Power Doppler Ultrasound Study. ReumatologÃ¤ ClÃ¤nica, 2022, 18, 273-278.	0.2	2
3	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. Internal and Emergency Medicine, 2022, 17, 475-480.	1.0	2
4	Impact of smoking habit on adult-onset Stillâ€™s disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	1.0	6
5	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. Joint Bone Spine, 2022, 89, 105299.	0.8	4
6	KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach. Biology, 2022, 11, 94.	1.3	0
7	Inflammatory muscle involvement in systemic vasculitis: A systematic review. Autoimmunity Reviews, 2022, 21, 103029.	2.5	12
8	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Stillâ€™s disease. Rheumatology, 2022, 61, 4124-4129.	0.9	16
9	Genotypeâ€“phenotype associations in familial Mediterranean fever: a study of 500 Egyptian pediatric patients. Clinical Rheumatology, 2022, 41, 1511-1521.	1.0	8
10	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. Ophthalmology and Therapy, 2022, 11, 899-911.	1.0	14
11	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. Ophthalmology and Therapy, 2022, 11, 887-897.	1.0	9
12	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	1.6	7
13	Neridronate for transient osteoporosis of the hip in a child. Osteoporosis International, 2022, 33, 1619-1624.	1.3	2
14	Routine IgG4 staining in minor salivary gland biopsy in a cohort of Italian Caucasian patients suffering from xerostomia. Reumatologia, 2022, 60, 12-15.	0.5	1
15	Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review. Life, 2022, 12, 317.	1.1	7
16	Effectiveness of rituximab in bullous Sweet's syndrome. International Journal of Dermatology, 2022, , .	0.5	2
17	Polymyalgia Rheumatica: A syndrome with an enthesitic subset? Comment on: â€œUse of 18F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practiceâ€•by Marie Pean de Ponfillyâ€“Sotier et al. Joint Bone Spine 2021;89:105325. Joint Bone Spine, 2022, 89, 105378.	0.8	1
18	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	1.2	9

#	Article	IF	Citations
19	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. Frontiers in Immunology, 2022, 13, 860877.	2.2	9
20	Doppler and Spectral Ultrasound of Sacroiliac Joints in Pediatric Patients with Suspected Juvenile Spondyloarthritis. Diagnostics, 2022, 12, 992.	1.3	2
21	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
22	Efficacy of intravenous neridronate in transient osteoporosis of the hip.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
23	Adalimumab for refractory idiopathic scleritis in children.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
24	OUP accepted manuscript. Rheumatology, 2022, , .	0.9	0
25	Diffuse Peripheral Enthesitis in Metabolic Syndrome: A Retrospective Clinical and Power Doppler Ultrasound Study. ReumatologÃ¤ ClÃ¬nica (English Edition), 2022, 18, 273-278.	0.2	0
26	Superb microvascular imaging in giant cell arteritis. Clinical and Experimental Rheumatology, 2022, , .	0.4	2
27	Adult-onset Still's disease with elderly onset, results from a multicentre study. Clinical and Experimental Rheumatology, 2022, , .	0.4	5
28	Development and implementation of the AIDA International Registry for patients with BehÃ§etâ€™s disease. Internal and Emergency Medicine, 2022, 17, 1977-1986.	1.0	11
29	Antirheumatic agents in covid-19: is IL-6 the right target?. Annals of the Rheumatic Diseases, 2021, 80, e2-e2.	0.5	15
30	COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Annals of the Rheumatic Diseases, 2021, 80, e14-e14.	0.5	50
31	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	2.0	16
32	Power and spectral Doppler ultrasound in suspected active sacroiliitis: a comparison with magnetic resonance imaging as gold standard. Rheumatology, 2021, 60, 1338-1345.	0.9	5
33	Giant cell arteritis presenting as aÂstroke in the internal carotid artery territory: aÂcase-based review. Reumatologia, 2021, 59, 121-125.	0.5	2
34	Ultrasound evaluation of the scapholunate ligament and scapholunate joint space in patients with wrist complaints in a rheumatologic setting. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ‚-SzopiÅ„ska, 2021, 21, e105-e111.	0.7	1
35	Difference in pain and accuracy of two hyaluronic acid injection techniques for symptomatic knee osteoarthritis in overweight patients. Reumatologia, 2021, 59, 23-26.	0.5	2
36	Low muscle mass and body composition analysis in aÂgroup of postmenopausal women affected by primary SjÃ¶grenâ€™s syndrome. Reumatologia, 2021, 59, 153-160.	0.5	2

#	Article	IF	Citations
37	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110371.	1.2	1
38	Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. Asia-Pacific Journal of Ophthalmology, 2021, 10, 360-365.	1.3	14
39	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. ELife, 2021, 10, .	2.8	145
40	Clinical profile and evolution of patients with juvenile-onset BehÃ§etâ€™s syndrome over a 25-year period: insights from the AIDA network. Internal and Emergency Medicine, 2021, 16, 2163-2171.	1.0	8
41	A novel grey scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale. Rheumatology, 2021, 61, 185-194.	0.9	9
42	Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: A narrative review. Autoimmunity Reviews, 2021, 20, 102784.	2.5	13
43	POS1349â€...THE JOINT INVOLVEMENT IN ADULT ONSET STILLâ€™S DISEASE IS CHARACTERISED BY A PECULIAR MAGNETIC RESONANCE IMAGING AND A SPECIFIC TRANSCRIPTOMIC PROFILE. Annals of the Rheumatic Diseases, 2021, 80, 957.1-957.	0.5	0
44	POS0661â€...RAPID RESPONSE TO BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE AND AT LEAST ONE BIOLOGIC DMARD: A CLINICAL AND POWER DOPPLER ULTRASOUND STUDY. Annals of the Rheumatic Diseases, 2021, 80, 573.1-573.	0.5	1
45	POS0832â€...A NOVEL GREY SCALE AND POWER DOPPLER ULTRASONOGRAPHIC SCORE FOR IDIOPATHIC INFLAMMATORY MYOPATHIES: SIENA MYOSITIS ULTRASOUND GRADING SCALE. Annals of the Rheumatic Diseases, 2021, 80, 669.1-670.	0.5	0
46	OP0093â€...RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLERâ€™S SYNDROME. Annals of the Rheumatic Diseases, 2021, 80, 51-52.	0.5	1
47	POS0963â€...POWER AND SPECTRAL DOPPLER ULTRASOUND AS A SCREENING TOOL IN THE DIAGNOSTIC COURSE OF SUSPECTED AXIAL SPONDYLOARTHRITIS: PRELIMINARY DATA FROM A LARGE MONOCENTRIC COHORT. Annals of the Rheumatic Diseases, 2021, 80, 746.2-747.	0.5	0
48	AB0380â€...MACHINE LEARNING CAN PREDICT GIANT CELL ARTERITIS RELAPSE AFTER GLUCOCORTICOID TAPERING. Annals of the Rheumatic Diseases, 2021, 80, 1217-1217.	0.5	0
49	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	0.9	4
50	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. Scientific Reports, 2021, 11, 12455.	1.6	10
51	Relapse of microscopic polyangiitis after vaccination against COVIDâ€19: A case report. Journal of Medical Virology, 2021, 93, 6439-6441.	2.5	13
52	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndromeâ€"Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	1.2	6
53	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. Trends in Cardiovascular Medicine, 2021, 31, 265-274.	2.3	31
54	Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with BehÃ§etâ€™s Syndrome. Ophthalmology and Therapy, 2021, 10, 1129-1135.	1.0	8

#	Article	IF	Citations
55	Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3218-3220.e1.	2.0	4
56	Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. Ophthalmology and Therapy, 2021, 10, 777-813.	1.0	11
57	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110336.	1.2	6
58	Bone-sparing effects of rituximab and body composition analysis in aÂcohort of postmenopausal women affected by rheumatoid arthritis â€“ retrospective study. Reumatologia, 2021, 59, 206-210.	0.5	9
59	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clinical and Experimental Rheumatology, 2021, 39, 187-195.	0.4	8
60	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 227.	0.4	1
61	Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. Clinical and Experimental Rheumatology, 2021, 39, 704.	0.4	0
62	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into BehÃ§et's Syndrome. Frontiers in Medicine, 2021, 8, 769870.	1.2	6
63	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 227-227.	0.4	6
64	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clinical and Experimental Rheumatology, 2021, 39, 187-195.	0.4	29
65	Atypical Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient with Polymyalgia Rheumatica and Giant Cell Arteritis. Current Health Sciences Journal, 2021, 47, 306-309.	0.2	0
66	Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. Clinical and Experimental Rheumatology, 2021, 39, 704-704.	0.4	3
67	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in BehÃ§etâ€™s Disease. Ocular Immunology and Inflammation, 2020, 28, 298-304.	1.0	46
68	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 956-964.	0.8	98
69	Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-Î± inhibition: a narrative review. Clinical Rheumatology, 2020, 39, 327-337.	1.0	12
70	The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis. Mediators of Inflammation, 2020, 2020, 1-9.	1.4	6
71	Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting. International Immunopharmacology, 2020, 86, 106748.	1.7	38
72	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. European Journal of Human Genetics, 2020, 28, 1602-1614.	1.4	208

#	Article	IF	Citations
73	Observations about subcalcaneal adventitial bursitis (heel fat pad inflammatory lesion) in rheumatoid arthritis. Comment on the article of Suzuki and Shirai. Reumatismo, 2020, 72, 182-183.	0.4	2
74	Discordance between patient and physician global assessment of disease activity in BehÃ§etâ€™s syndrome: a multicenter study cohort. Arthritis Research and Therapy, 2020, 22, 278.	1.6	7
75	The current status of biological treatment for uveitis. Expert Review of Clinical Immunology, 2020, 16, 787-811.	1.3	15
76	Development and preliminary validation of the BehÃ§etâ€™s syndrome Overall Damage Index (BODI). RMD Open, 2020, 6, e001192.	1.8	20
77	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Stillâ€™s Disease. Mediators of Inflammation, 2020, 2020, 1-7.	1.4	18
78	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Î± Receptorâ€"Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	1.4	24
79	Safety of systemic treatments for BehÃ§etâ€™s syndrome. Expert Opinion on Drug Safety, 2020, 19, 1269-1301.	1.0	6
80	Inflammatory Bowel Diseases and Coexisting Spondyloarthritis: A Neglected and too Often Under-Reported Association by Radiologists. A Multicenter Study by Italian Research Group of Imaging in Rheumatology. Gastroenterology Insights, 2020, 11, 47-57.	0.7	2
81	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	7
82	Response to: â€˜Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?â€™ by Fayand et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2019-216862.	0.5	0
83	Long-Term Outcomes of BehÃ§etâ€™s Syndrome-Related Uveitis: A Monocentric Italian Experience. Mediators of Inflammation, 2020, 2020, 1-8.	1.4	12
84	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Frontiers in Immunology, 2020, 11, 865.	2.2	48
85	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
86	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on BehÃ§etâ€™s syndrome. Inflammopharmacology, 2020, 28, 711-718.	1.9	19
87	The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Stillâ€™s disease. A systematic review and meta-analysis of observational studies. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093313.	1.2	16
88	Intramuscular Clodronate in Long-Term Treatment of Symptomatic Knee Osteoarthritis: A Randomized Controlled Study. Drugs in R and D, 2020, 20, 39-45.	1.1	12
89	BehÃ§etâ€™s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Internal and Emergency Medicine, 2020, 15, 1031-1039.	1.0	13
90	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. Mediators of Inflammation, 2020, 2020, 1-5.	1.4	20

#	Article	IF	Citations
91	OP0273â€...ADHERENCE TO COLCHICINE TREATMENT AND COLCHICINE RESISTANCE IN A MULTICENTRIC FMF NATIONAL COHORT. Annals of the Rheumatic Diseases, 2020, 79, 170-171.	0.5	2
92	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	15
93	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096403.	1.2	21
94	Anterior chest wall non-traumatic diseases: a road map for the radiologist. Acta Biomedica, 2020, 91, 43-50.	0.2	3
95	Polymyalgia rheumatica following infective triggersor vaccinations: a different subset of disease?. Reumatologia, 2020, 58, 76-80.	0.5	11
96	AB0281â€...SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.. Annals of the Rheumatic Diseases, 2020, 79, 1439.1-1440.	0.5	0
97	THU0520â€...DIFFUSE ENTHESITIS AND LOW-GRADE INFLAMMATION IN PATIENTS WITH METABOLIC SYNDROME: A CLINICAL AND ULTRASOUND STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 499.1-499.	0.5	0
98	FRI0457â€...LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS) FROM THE EUROFEVER INTERNATIONAL REGISTRY. Annals of the Rheumatic Diseases, 2020, 79, 825.2-826.	0.5	0
99	AB1086â€...POWER DOPPLER AND SPECTRAL DOPPLER ULTRASOUND IN SUSPECTED ACTIVE SACROILIITIS: A COMPARISON WITH MAGNETIC RESONANCE IMAGING AS GOLD STANDARD. Annals of the Rheumatic Diseases, 2020, 79, 1832.1-1832.	0.5	0
100	AB0939â€...POLYMYALGIA RHEUMATICA FOLLOWING INFECTIVE TRIGGERS OR VACCINATIONS: A DIFFERENT SUBSET OF DISEASE?. Annals of the Rheumatic Diseases, 2020, 79, 1769.3-1769.	0.5	0
101	SAT0243â€...SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1064-1065.	0.5	0
102	Efficacy of monoclonal anti-tumour necrosis factor-Î± antibodies in uveitic macular oedema. Clinical and Experimental Rheumatology, 2020, 38, 621-625.	0.4	0
103	Reply to Praprotnik and Tomsic and erratum corrige. Clinical and Experimental Rheumatology, 2020, 38, 1034.	0.4	0
104	Effectiveness of TNF-Î± blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clinical and Experimental Rheumatology, 2020, 38, 1138-1144.	0.4	4
105	Anti-dense fine speckled 70 antibodies in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 326.	0.4	1
106	Polidistrectual videocapillaroscopic evaluation in a patient with prolidase deficiency. Clinical and Experimental Rheumatology, 2020, 38, 1265-1266.	0.4	1
107	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clinical Rheumatology, 2019, 38, 407-415.	1.0	56
108	Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Annals of the Rheumatic Diseases, 2019, 78, 1405-1411.	0.5	44

#	Article	IF	Citations
109	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	1.6	25
110	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Medicine, 2019, 16, e1002901.	3.9	94
111	Long-Term Retention Rate of Anakinra in Adult Onset Stillâ€™s Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
112	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. International Journal of Molecular Sciences, 2019, 20, 1898.	1.8	60
113	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.5	300
114	Magnetic resonance imaging of the sacroiliac joints in SpA: with or without intravenous contrast media? A preliminary report. Radiologia Medica, 2019, 124, 1142-1150.	4.7	9
115	The right place of interleukin-1 inhibitors in the treatment of BehÃ§etâ€™s syndrome: a systematic review. Rheumatology International, 2019, 39, 971-990.	1.5	38
116	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. Mediators of Inflammation, 2019, 2019, 1-8.	1.4	27
117	THU0517â€...THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT. , 2019, , .		0
118	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. Frontiers in Pharmacology, 2019, 10, 1468.	1.6	19
119	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Frontiers in Pharmacology, 2019, 10, 1497.	1.6	12
120	Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases. Mediators of Inflammation, 2019, 2019, 1-29.	1.4	17
121	Real-world effectiveness of apremilast in multirefractory mucosal involvement of BehÃ§etâ€™s disease. Annals of the Rheumatic Diseases, 2019, 78, 1736-1737.	0.5	21
122	Comment on: Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology, 2019, 60, e270-e271.	0.9	1
123	Management of adult-onset Stillâ€™s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Research and Therapy, 2019, 21, 275.	1.6	20
124	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with BehÃ§etâ€™s disease. Internal and Emergency Medicine, 2019, 14, 719-722.	1.0	13
125	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€"associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	1.0	16
126	Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review. Clinical Rheumatology, 2019, 38, 11-17.	1.0	45

#	Article	IF	Citations
127	Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with BehÃ§etâ€™s Disease. Ocular Immunology and Inflammation, 2019, 27, 58-63.	1.0	40
128	Ten-Year Retention Rate of Infliximab in Patients with BehÃ§etâ€™s Disease-Related Uveitis. Ocular Immunology and Inflammation, 2019, 27, 34-39.	1.0	37
129	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clinical Rheumatology, 2019, 38, 63-70.	1.0	29
130	Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. Clinical and Experimental Immunology, 2019, 199, 88-96.	1.1	14
131	Efficacy of anti-tumour necrosis factor-Î± monoclonal antibodies in patients with non-infectious anterior uveitis. Clinical and Experimental Rheumatology, 2019, 37, 301-305.	0.4	8
132	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clinical and Experimental Rheumatology, 2019, 37, 680-683.	0.4	19
133	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. Clinical and Experimental Rheumatology, 2019, 37, 762-767.	0.4	10
134	Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 159-160.	0.4	0
135	Adalimumabâ€Based Treatment Versus Diseaseâ€Modifying Antirheumatic Drugs for Venous Thrombosis in BehÃ§et's Syndrome. Arthritis and Rheumatology, 2018, 70, 1500-1507.	2.9	57
136	Predictors of sustained clinical response in patients with BehÃ§etâ€™s disease-related uveitis treated with infliximab and adalimumab. Clinical Rheumatology, 2018, 37, 1715-1720.	1.0	21
137	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	1.0	48
138	A Comprehensive Overview of the Hereditary Periodic Fever Syndromes. Clinical Reviews in Allergy and Immunology, 2018, 54, 446-453.	2.9	42
139	Biological therapies for the treatment of BehÃ§etâ€™s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatology International, 2018, 38, 25-35.	1.5	15
140	Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. Rheumatology, 2018, 57, 100-111.	0.9	67
141	Cumulative retention rate of adalimumab in patients with BehÃ§etâ€™s disease-related uveitis: a four-year follow-up study. British Journal of Ophthalmology, 2018, 102, 637-641.	2.1	44
142	AB0709â€…Switching from originator infliximab to biosimilar infliximab: efficacy and safety in a cohort of patients with established behÃ‡etâ€™s disease. , 2018, , .		1
143	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. Journal of Clinical Medicine, 2018, 7, 504.	1.0	61
144	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcetâ€™s disease. Immunology Letters, 2018, 201, 38-44.	1.1	24

#	Article	IF	Citations
145	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clinical Rheumatology, 2018, 37, 2805-2809.	1.0	35
146	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
147	Autoinflammatory Diseases. , 2018, , 371-377.		1
148	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
149	Influence of baseline modified Rheumatic Disease Comorbidity Index (<scp>mRDCI</scp>) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in realâ€world settings. European Journal of Clinical Investigation, 2018, 48, e13013.	1.7	42
150	Clodronate in the management of different musculoskeletal conditions. Minerva Medica, 2018, 109, 300-325.	0.3	21
151	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. Current Cardiology Reports, 2018, 20, 61.	1.3	29
152	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2018, 9, 1526.	1.6	15
153	SAT0307â€…Impact of the modified rheumatic disease comorbidity index(MRDCI) on drug survival of first line anti-tnfÎ± drugs in patents affected with psoriatic arthritis in real life setting. , 2018, , .		0
154	SAT0223â€…Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry.. , 2018, , .		0
155	SAT0193â€…Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry. , 2018, , .		0
156	FRI0075â€…Risk of hepatitis b infection reactivation in rheumatic diseases patients treated with anti-cd20 therapy. , 2018, , .		0
157	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clinical and Experimental Rheumatology, 2018, 36, 668-675.	0.4	31
158	Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 3-9.	0.4	12
159	Musculoskeletal manifestations in hereditary periodic fever syndromes. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 25-31.	0.4	0
160	The eye involvement in monogenic autoinflammatory diseases: literature review and update. Clinical and Experimental Rheumatology, 2018, 36 Suppl 110, 44-53.	0.4	4
161	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with BehÃ§et's Disease. Israel Medical Association Journal, 2018, 20, 517-521.	0.1	3
162	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. Israel Medical Association Journal, 2018, 20, 438-441.	0.1	7

#	Article	IF	Citations
163	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. Clinical and Experimental Rheumatology, 2018, 36, 68-73.	0.4	15
164	Serum immunoglobulin D levels in patients with BehÃ§et's disease according to different clinical manifestations. Clinical and Experimental Rheumatology, 2018, 36, 110-115.	0.4	8
165	Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. Clinical Reviews in Allergy and Immunology, 2017, 52, 34-44.	2.9	14
166	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clinical Rheumatology, 2017, 36, 463-468.	1.0	64
167	Canakinumab efficacy in refractory adultâ€onset <scp>PFAPA</scp> syndrome. International Journal of Rheumatic Diseases, 2017, 20, 1050-1051.	0.9	31
168	Longâ€term efficacy and safety of anakinra in a patient with BehÃ§et's disease and concomitant tuberculosis infection. International Journal of Dermatology, 2017, 56, 218-220.	0.5	17
169	Safety profile of biologic agents for BehÃ§et's disease in a multicenter observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 103-108.	0.9	22
170	Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. Expert Opinion on Orphan Drugs, 2017, 5, 165-171.	0.5	14
171	The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clinical Rheumatology, 2017, 36, 2307-2318.	1.0	35
172	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
173	Certolizumab Pegol treatment in Behcetâ€™s disease with different organ involvement: A multicenter retrospective observational study. Modern Rheumatology, 2017, 27, 1031-1035.	0.9	38
174	The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experienceÂfromÂa referral center in Italy. Internal and Emergency Medicine, 2017, 12, 605-611.	1.0	13
175	Long-term efficacy and safety of golimumab in the treatment of multirefractory BehÃ§etâ€™s disease. Clinical Rheumatology, 2017, 36, 2063-2069.	1.0	36
176	Quality of life impairment in BehÃ§etâ€™s disease and relationship with disease activity: a prospective study. Internal and Emergency Medicine, 2017, 12, 947-955.	1.0	46
177	IL-6 blockade in the management of non-infectious uveitis. Clinical Rheumatology, 2017, 36, 1459-1469.	1.0	33
178	Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 549-555.	0.6	11
179	Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. Clinical Rheumatology, 2017, 36, 1687-1690.	1.0	22
180	Rapid desensitization to anakinraâ€related delayed reaction: Need for a standardized protocol. Journal of Dermatology, 2017, 44, 981-982.	0.6	9

#	Article	IF	Citations
181	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.5	175
182	Interleukin (IL)-1 inhibition with anakinra and canakinumab in BehÃ§etâ€™s disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 191-197.	1.0	115
183	THU0155â€...Impact of baseline modified rheumatic disease comorbidity index (MRDCI) on drug survival and effectiveness of biological drugs in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SPA), and psoriatic arthritis (PSA) in real-world settings. , 2017, , .		0
184	Systemic Vasculopathy in a Patient With Tumor Necrosis Factor Receptorâ€"Associated Periodic Syndrome. Journal of Clinical Rheumatology, 2017, 23, 395-397.	0.5	3
185	THU0541â€...Role of IL-1 inhibition in adult onset still's disease (AOSD): a retrospective, observational multicentric study from the italian society of rheumatology study group on autoinflammatory diseases. , 2017, , .		0
186	Longâ€term efficacy and safety of the interleukinâ€1 inhibitors anakinra and canakinumab in refractory BehÃ§et disease uveitis and concomitant bladder papillary carcinoma. Internal Medicine Journal, 2017, 47, 1086-1088.	0.5	11
187	Efficacy and safety of adalimumab in BehÃ§etâ€™s disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 183-189.	1.0	84
188	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptorâ€"Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	1.5	75
189	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2017, 36, 469-475.	1.0	45
190	Auditory involvement in Behcetâ€™s disease: relationship with demographic, clinical, and therapeutic characteristics. Clinical Rheumatology, 2017, 36, 445-449.	1.0	9
191	Adalimumab effectiveness in BehÃ§etâ€™s disease: short and long-term data from a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 451-455.	1.0	52
192	Interleukinâ€1 blockade in neuroâ€‹<scp>B</scp>ehÃ§et's disease: a caseâ€based reflection. International Journal of Rheumatic Diseases, 2017, 20, 1046-1049.	0.9	11
193	AB0037â€...Serum cytokine signature in mucocutaneous and ocular behÃ‡et's disease. , 2017, , .		1
194	A national cohort study on pediatric BehÃ§etâ€™s disease: cross-sectional data from an Italian registry. Pediatric Rheumatology, 2017, 15, 84.	0.9	55
195	AB1160â€...Epidemiology and clinical presentation of ocular involvement in a population of 278 patients with non infectious uveitis. , 2017, , .		0
196	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Stillâ€™s Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
197	Update on the Medical Management of Gastrointestinal BehÃ§etâ€™s Disease. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	16
198	Cytokine Signatures in Mucocutaneous and Ocular BehÃ§etâ€™s Disease. Frontiers in Immunology, 2017, 8, 200.	2.2	50

#	Article	IF	Citations
199	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2017, 8, 1018.	2.2	37
200	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Clinical and Experimental Rheumatology, 2017, 35, 170-171.	0.4	2
201	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. Clinical and Experimental Rheumatology, 2017, 35, 93-97.	0.4	7
202	Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2017, 35 Suppl 104, 13-14.	0.4	0
203	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clinical and Experimental Rheumatology, 2017, 35, 660-665.	0.4	5
204	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in BehÃ§et's Disease. Israel Medical Association Journal, 2017, 19, 415-419.	0.1	7
205	Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome. Israel Medical Association Journal, 2017, 19, 444-447.	0.1	15
206	Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. Israel Medical Association Journal, 2017, 19, 478-483.	0.1	19
207	Ustekinumab efficacy and safety in mucocutaneous multi-refractory BehÃ§et's disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 130-131.	0.4	5
208	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
209	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	2.9	168
210	SAT0564â€…Articular Involvement in BehÃ§et Disease: An Ultrasonographic Study. Annals of the Rheumatic Diseases, 2016, 75, 873.2-873.	0.5	0
211	Recurrent pericarditis in children and adolescents. Journal of Cardiovascular Medicine, 2016, 17, 707-712.	0.6	61
212	Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-Î± in early phases of the disease. Medicine (United States), 2016, 95, e5516.	0.4	43
213	Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory BehÃ§et×³s disease. Seminars in Arthritis and Rheumatism, 2016, 46, e1-e2.	1.6	25
214	Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internistsâ€™ lens. Internal and Emergency Medicine, 2016, 11, 781-791.	1.0	10
215	Adult-onset Stillâ€™s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	1.0	83
216	Clinical Characteristics of Patients Carrying the Q703K Variant of the NLRP3 Gene: A 10-year Multicentric National Study. Journal of Rheumatology, 2016, 43, 1093-1100.	1.0	31

#	Article	IF	Citations
217	Management of Small Vessel Vasculitides. Current Rheumatology Reports, 2016, 18, 36.	2.1	9
218	New therapeutic solutions for BehÃ§etâ€™s syndrome. Expert Opinion on Investigational Drugs, 2016, 25, 827-840.	1.9	36
219	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology, 2016, 35, 2631-2638.	1.0	28
220	Drug survival of adalimumab in patients with rheumatoid arthritis over 10Âyears in the real-world settings: high rate remission together with normal function ability. Clinical Rheumatology, 2016, 35, 2649-2656.	1.0	19
221	Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opinion on Biological Therapy, 2016, 16, 1311-1312.	1.4	30
222	Immunometabolic biomarkers of inflammation in BehÃ§et's disease: relationship with epidemiological profile, disease activity and therapeutic regimens. Clinical and Experimental Immunology, 2016, 184, 197-207.	1.1	28
223	PFAPA syndrome and BehÃ§etâ€™s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	1.0	28
224	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmunity Reviews, 2016, 15, 447-450.	2.5	54
225	Genetic aspects of the antiphospholipid syndrome: An update. Autoimmunity Reviews, 2016, 15, 433-439.	2.5	36
226	Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	1.5	15
227	Smoke and autoimmunity: The fire behind the disease. Autoimmunity Reviews, 2016, 15, 354-374.	2.5	143
228	Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective. Clinical Rheumatology, 2016, 35, 565-572.	1.0	9
229	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. Journal of Rheumatology, 2016, 43, 911-917.	1.0	19
230	Developing a Predictive Score for Chronic Arthritis among a Cohort ofÂChildren with Musculoskeletal Complaintsâ€"The Chronic Arthritis ScoreÂStudy. Journal of Pediatrics, 2016, 169, 188-193.	0.9	5
231	Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. Current Rheumatology Reports, 2016, 18, 3.	2.1	55
232	Consensus classification criteria for paediatric BehÃ§et's disease from a prospective observational cohort: PEDBD. Annals of the Rheumatic Diseases, 2016, 75, 958-964.	0.5	169
233	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	1.0	52
234	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. Clinical Rheumatology, 2016, 35, 19-23.	1.0	10

#	Article	IF	Citations
235	Efficacy and safety profile of anti-interleukin-1 treatment in BehÃ§etâ€™s disease: a multicenter retrospective study. Clinical Rheumatology, 2016, 35, 1281-1286.	1.0	95
236	Development of de novo major involvement during follow-up in BehÃ§etâ€™s syndrome. Clinical Rheumatology, 2016, 35, 247-250.	1.0	9
237	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Clinical and Experimental Rheumatology, 2016, 34, 424-9.	0.4	11
238	Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?. Clinical and Experimental Rheumatology, 2016, 34, 961-962.	0.4	3
239	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clinical and Experimental Rheumatology, 2016, 34, 531-8.	0.4	23
240	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. Clinical and Experimental Rheumatology, 2016, 34, 353.	0.4	7
241	Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-Î± therapy. Clinical and Experimental Rheumatology, 2016, 34, 507-12.	0.4	10
242	Interleukin-1 Inhibition in BehÃ§et's disease. Israel Medical Association Journal, 2016, 18, 171-6.	0.1	26
243	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Israel Medical Association Journal, 2016, 18, 238-42.	0.1	18
244	One year in review 2016: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 357-72.	0.4	17
245	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. Clinical and Experimental Rheumatology, 2016, 34, 77-81.	0.4	21
246	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. Medicine (United States), 2015, 94, e1858.	0.4	31
247	Delights and letâ€downs in the management of tumor necrosis factor receptorâ€associated periodic syndrome: the canakinumab experience in a patient with a highâ€penetrance T50M <scp>TNFRSF</scp>1A variant. International Journal of Rheumatic Diseases, 2015, 18, 473-475.	0.9	5
248	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. Journal of Medical Case Reports, 2015, 9, 123.	0.4	28
249	Safety of longâ€term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology, 2015, 62, 40-46.	3.6	82
250	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with BehÃ§et's disease. Pediatric Rheumatology, 2015, 13, .	0.9	3
251	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	41
252	Mucocutaneous Involvement in BehÃ§etâ€™s Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	22

#	Article	IF	Citations
253	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-21.	1.4	79
254	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. Medicine (United States), 2015, 94, e1528.	0.4	51
255	Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis. Medicine (United States), 2015, 94, e1170.	0.4	9
256	The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study. Pediatric Rheumatology, 2015, 13, 38.	0.9	5
257	Safety issues and concerns of new immunomodulators in rheumatology. Expert Opinion on Drug Safety, 2015, 14, 389-399.	1.0	34
258	Current evidence in the field of the management with TNF-Î± inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opinion on Biological Therapy, 2015, 15, 641-650.	1.4	31
259	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.5	215
260	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.5	180
261	Anakinra treatment in drug-resistant Behcetâ€™s disease: a case series. Clinical Rheumatology, 2015, 34, 1293-1301.	1.0	114
262	Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clinical Rheumatology, 2015, 34, 1817-1820.	1.0	29
263	Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunologic Research, 2015, 61, 326-337.	1.3	30
264	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.5	145
265	Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatology International, 2015, 35, 1943-1947.	1.5	39
266	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.5	239
267	Seronegative reactive spondyloarthritis and the skin. Clinics in Dermatology, 2015, 33, 531-537.	0.8	12
268	Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clinical Rheumatology, 2015, 34, 1333-1339.	1.0	56
269	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clinical Rheumatology, 2015, 34, 1171-1180.	1.0	15
270	The 2014 ACR annual meeting: a birdâ€™s eye view of autoimmunity in 2015. Autoimmunity Reviews, 2015, 14, 622-632.	2.5	10

#	Article	IF	Citations
271	Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clinical Rheumatology, 2015, 34, 1503-1511.	1.0	20
272	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link interwinding obesity and osteoarthritis?. Annals of the Rheumatic Diseases, 2015, 74, e70-e70.	0.5	2
273	Ocular Involvement in Systemic Autoimmune Diseases. Clinical Reviews in Allergy and Immunology, 2015, 49, 263-270.	2.9	67
274	Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open, 2015, 1, e000097.	1.8	103
275	Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. Clinical Rheumatology, 2015, 34, 391-395.	1.0	25
276	Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1Î² monoclonal antibody canakinumab. Clinical Rheumatology, 2015, 34, 1311-1316.	1.0	31
277	Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunologic Research, 2015, 61, 147-153.	1.3	70
278	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmunity Reviews, 2015, 14, 90-97.	2.5	55
279	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clinical Rheumatology, 2015, 34, 17-28.	1.0	37
280	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of BehÃ§et's disease. Autoimmunity Reviews, 2015, 14, 1-9.	2.5	79
281	Possible chondroprotective effect of canakinumab: An in vitro study on human osteoarthritic chondrocytes. Cytokine, 2015, 71, 165-172.	1.4	25
282	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clinical Rheumatology, 2015, 34, 807-809.	1.0	20
283	Paradoxical mucocutaneous flare in a case of BehÃ§etâ€™s disease treated with tocilizumab. Clinical Rheumatology, 2015, 34, 1141-1143.	1.0	51
284	Anakinra treatment in patients with gout and type 2 diabetes. Clinical Rheumatology, 2015, 34, 981-984.	1.0	38
285	Bilateral dexamethasone intravitreal implant in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis. Clinical Rheumatology, 2015, 34, 1145-1148.	1.0	21
286	One year in review: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 102-8.	0.4	11
287	Adult-onset autoinflammatory disorders: a still debated entity?. Clinical and Experimental Rheumatology, 2015, 33, 137-40.	0.4	5
288	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. Clinical and Experimental Rheumatology, 2015, 33, S171-2.	0.4	6

#	Article	IF	Citations
289	Effects of tumor necrosis factor-Î± inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis. Clinical and Experimental Rheumatology, 2015, 33, 411-3.	0.4	0
290	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. Israel Medical Association Journal, 2015, 17, 93-7.	0.1	18
291	Efficacy and safety of abatacept in a patient with rheumatoid arthritis and concomitant Staphylococcus aureus osteomyelitis. Clinical and Experimental Rheumatology, 2015, 33, 947-8.	0.4	0
292	Untangling the Web of Systemic Autoinflammatory Diseases. Mediators of Inflammation, 2014, 2014, 1-15.	1.4	25
293	Drug Retention Rates and Treatment Discontinuation among Anti-TNF-Î±Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	49
294	Biological Treatments in BehÃ§etâ€™s Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation, 2014, 2014, 1-14.	1.4	68
295	Current Advances in the Understanding and Treatment of Mevalonate Kinase Deficiency. International Journal of Immunopathology and Pharmacology, 2014, 27, 491-498.	1.0	35
296	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.5	256
297	Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and/or low molecular weight heparin. Pediatric Rheumatology, 2014, 12, 47.	0.9	9
298	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. Pediatric Rheumatology, 2014, 12, 49.	0.9	6
299	Simple clinical indicators for early psoriatic arthritis detection. SpringerPlus, 2014, 3, 759.	1.2	42
300	Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory BehÃ§et's Disease: A Case Series. Dermatology, 2014, 228, 211-214.	0.9	74
301	Blau syndrome and latent tubercular infection: an unresolved partnership. International Journal of Rheumatic Diseases, 2014, 17, 586-587.	0.9	6
302	Long-Term Efficacy of Interleukin-1 Receptor Antagonist (Anakinra) in Corticosteroid-Dependent and Colchicine-Resistant Recurrent Pericarditis. Journal of Pediatrics, 2014, 164, 1425-1431.e1.	0.9	94
303	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	1.6	71
304	The use of TNF-Î± blockers in psoriatic arthritis patients with latent tuberculosis infection. Clinical Rheumatology, 2014, 33, 543-547.	1.0	34
305	The purinergic <scp>P</scp>2Ã—7 receptor is expressed on monocytes in <scp>B</scp>ehÃ§et's disease and is modulated by <scp>TNF</scp>â€Î±. European Journal of Immunology, 2014, 44, 227-238.	1.6	22
306	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmunity Reviews, 2014, 13, 1220-1229.	2.5	86

#	Article	IF	Citations
307	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.5	92
308	Serum amyloid-A in BehÃ§etâ€™s disease. Clinical Rheumatology, 2014, 33, 1165-1167.	1.0	14
309	Working the endless puzzle of hereditary autoinflammatory disorders. Modern Rheumatology, 2014, 24, 381-389.	0.9	20
310	The hereditary autoinflammatory disorders uncovered. Autoimmunity Reviews, 2014, 13, 892-900.	2.5	53
311	Key facts and hot spots on tumor necrosis factor receptorâ€associated periodic syndrome. Clinical Rheumatology, 2014, 33, 1197-1207.	1.0	58
312	Diagnosis and classification of relapsing polychondritis. Journal of Autoimmunity, 2014, 48-49, 53-59.	3.0	77
313	Efficacy of anakinra in refractory BehÃ§et's disease sacroiliitis. Clinical and Experimental Rheumatology, 2014, 32, S171.	0.4	18
314	Weekly oral alendronate in mevalonate kinase deficiency. Orphanet Journal of Rare Diseases, 2013, 8, 196.	1.2	19
315	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.5	350
316	Improved Efficacy of Intramuscular Weekly Administration of Clodronate 200Âmg (100Âmg Twice) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Osteoporosis. Clinical Drug Investigation, 2013, 33, 193-198.	1.1	5
317	Role of Autoimmunity and Autoinflammation in the Pathogenesis of Idiopathic Recurrent Pericarditis. Clinical Reviews in Allergy and Immunology, 2013, 44, 6-13.	2.9	38
318	Antiangiogenic VEGF Isoform in Inflammatory Myopathies. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	19
319	Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. Mediators of Inflammation, 2013, 2013, 1-16.	1.4	64
320	Caution Should be Used in the Recognition of Adult-Onset Autoinflammatory Disorders: Facts or Fiction?. Frontiers in Immunology, 2013, 4, 96.	2.2	5
321	From the Mediterranean to the Sea of Japan: The Transcontinental Odyssey of Autoinflammatory Diseases. BioMed Research International, 2013, 2013, 1-8.	0.9	54
322	The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. International Journal of Rheumatic Diseases, 2013, 16, 495-496.	0.9	5
323	Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues. International Journal of Rheumatology, 2013, 2013, 1-15.	0.9	67
324	Severe Macular Edema in Patients with Juvenile Idiopathic Arthritis-Related Uveitis. Case Reports in Ophthalmological Medicine, 2013, 2013, 1-5.	0.3	9

#	Article	IF	Citations
325	Expanding spectrum of <scp>TNFRSF1A</scp> gene mutations among patients with idiopathic recurrent acute pericarditis. Internal Medicine Journal, 2013, 43, 725-727.	0.5	13
326	SAT0466â€...PED-BD COHORT 2013: Expert Consensus Classification Gives Higher Sensitivity than the International Study Group Criteria to Define Behcetâ€™s Disease in Children. Annals of the Rheumatic Diseases, 2013, 72, A739.1-A739.	0.5	0
327	THU0376â€...Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 282.3-283.	0.5	1
328	Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo, 2013, 65, 55-62.	0.4	22
329	AB1226â€...Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: A preliminary report. Annals of the Rheumatic Diseases, 2013, 71, 707.18-708.	0.5	0
330	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	1.1	44
331	Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report. Clinical and Experimental Rheumatology, 2013, 31, 207-12.	0.4	8
332	The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clinical and Experimental Rheumatology, 2013, 31, 141-9.	0.4	24
333	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2012, 71, 2035-2043.	0.5	69
334	Successful Treatment of Tumor Necrosis Factor Receptorâ€"Associated Periodic Syndrome With Canakinumab. Annals of Internal Medicine, 2012, 156, 907.	2.0	41
335	Recurrent pericarditis: Autoimmune or autoinflammatory?. Autoimmunity Reviews, 2012, 12, 60-65.	2.5	73
336	Clinical and biochemical landmarks in systemic autoinflammatory diseases. Annals of Medicine, 2012, 44, 664-673.	1.5	34
337	The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: Our experience and review of the literature. Autoimmunity Reviews, 2012, 12, 10-13.	2.5	47
338	Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): State of the art and future perspectives. Autoimmunity Reviews, 2012, 12, 38-43.	2.5	92
339	Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opinion on Investigational Drugs, 2012, 21, 1-6.	1.9	22
340	Typical and severe tumor necrosis factor receptorâ€"associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatology International, 2012, 32, 4015-4018.	1.5	15
341	Kawasaki syndrome and concurrent Coxsackie virus B3 infection. Rheumatology International, 2012, 32, 4037-4040.	1.5	14
342	Serum Amyloid A Circulating Levels and Disease Activity in Patients with Juvenile Idiopathic Arthritis. Yonsei Medical Journal, 2012, 53, 1045.	0.9	23

#	Article	IF	Citations
343	What Do Cytokine Profiles Tell Us About Subsets of Juvenile Idiopathic Arthritis?. Current Rheumatology Reports, 2012, 14, 150-154.	2.1	7
344	Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease. Rheumatology International, 2012, 32, 1481-1482.	1.5	10
345	Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clinical Research in Cardiology, 2012, 101, 525-531.	1.5	97
346	Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene. Rheumatology International, 2012, 32, 465-467.	1.5	16
347	Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. Clinical and Experimental Rheumatology, 2012, 30, 269-71.	0.4	48
348	Successful use of canakinumab in a patient with resistant BehÃ§et's disease. Clinical and Experimental Rheumatology, 2012, 30, S115.	0.4	35
349	A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. Clinical and Experimental Rheumatology, 2012, 30, 593.	0.4	37
350	Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2012, 30, S108-14.	0.4	5
351	Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. Clinical and Experimental Rheumatology, 2012, 30, 943-6.	0.4	29
352	Autoinflammatory diseases and cardiovascular manifestations. Annals of Medicine, 2011, 43, 341-346.	1.5	61
353	Bridging the Gap between the Clinician and the Patient with Cryopyrin-Associated Periodic Syndromes. International Journal of Immunopathology and Pharmacology, 2011, 24, 827-836.	1.0	56
354	Monogenic autoinflammatory syndromes at a dermatological level. Archives of Dermatological Research, 2011, 303, 375-380.	1.1	17
355	Effects of Spa therapy on serum leptin and adiponectin levels in patients with knee osteoarthritis. Rheumatology International, 2011, 31, 879-882.	1.5	41
356	Autoinflammatory disorders and patients with isolated serosal involvement. Rheumatology International, 2011, 31, 979-980.	1.5	3
357	Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?. Rheumatology International, 2011, 31, 1-8.	1.5	177
358	Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults. International Journal of Immunopathology and Pharmacology, 2011, 24, 695-702.	1.0	50
359	Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology, 2011, 50, 184-188.	0.9	73
360	Partial Rescue of Biochemical Parameters After Hematopoietic Stem Cell Transplantation in a Patient with Prolidase Deficiency Due to Two Novel PEPD Mutations. JIMD Reports, 2011, 3, 71-77.	0.7	11

#	Article	IF	Citations
361	Large pericardial effusion in a family with recurrent pericarditis: A report of probable x-linked transmission. Experimental and Clinical Cardiology, 2011, 16, 54-6.	1.3	7
362	Circulating levels of the adipokines vaspin and omentin in patients with juvenile idiopathic arthritis, and relation to disease activity. Clinical and Experimental Rheumatology, 2011, 29, 1044-8.	0.4	14
363	Short- and Long-Term Effects of Spa Therapy in Knee Osteoarthritis. American Journal of Physical Medicine and Rehabilitation, 2010, 89, 125-132.	0.7	68
364	Colchicine Myopathy and Neuromyopathy. Journal of Clinical Rheumatology, 2010, 16, 229-232.	0.5	19
365	Efficacy of cyclosporine A treatment in relapsing febrile lobular panniculitis associated with small vessel vasculitis. Rheumatology International, 2010, 30, 797-799.	1.5	7
366	Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmunity Reviews, 2010, 9, 436-440.	2.5	28
367	Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmunity Reviews, 2010, 9, 674-683.	2.5	86
368	Possible Implication of Local Immune Response in Darier's Disease: An Immunohistochemical Characterization of Lesional Inflammatory Infiltrate. Mediators of Inflammation, 2010, 2010, 1-8.	1.4	2
369	Serosal Involvement in Adult-Onset Autoinflammatory Disorders. Respiration, 2010, 80, 260-261.	1.2	6
370	Development and Preliminary Validation of a Diagnostic Score for Identifying Patients Affected with Adult-Onset Autoinflammatory Disorders. International Journal of Immunopathology and Pharmacology, 2010, 23, 1133-1141.	1.0	32
371	Role of Etanercept in the Treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Personal Experience and Review of the Literature. International Journal of Immunopathology and Pharmacology, 2010, 23, 701-707.	1.0	51
372	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Annals of the Rheumatic Diseases, 2010, 69, 798-806.	0.5	1,073
373	Retinal Complications of Juvenile Idiopathic Arthritis-related Uveitis: A Microperimetry and Optical Coherence Tomography Study. Ocular Immunology and Inflammation, 2010, 18, 54-59.	1.0	33
374	Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clinical and Experimental Rheumatology, 2010, 28, 290-1.	0.4	22
375	Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clinical and Experimental Rheumatology, 2010, 28, 405-7.	0.4	49
376	Familial Mediterranean fever diagnosed in an elderly patient. Clinical and Experimental Rheumatology, 2010, 28, S91.	0.4	12
377	Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clinical and Experimental Rheumatology, 2010, 28, 802.	0.4	43
378	Th17 Transcription Factor RORC2 Is Inversely Correlated with FOXP3 Expression in the Joints of Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 2017-2024.	1.0	33

#	Article	IF	Citations
379	Eosinophilia-associated muscle disorders: an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms. Journal of Clinical Pathology, 2009, 62, 442-447.	1.0	14
380	Safety and Efficacy of Etanercept in Children with Juvenile-Onset Behcet's Disease. International Journal of Immunopathology and Pharmacology, 2009, 22, 551-555.	1.0	38
381	Idiopathic Recurrent Pericarditis Refractory to Colchicine Treatment Can Reveal Tumor Necrosis Factor Receptor-Associated Periodic Syndrome. International Journal of Immunopathology and Pharmacology, 2009, 22, 1051-1058.	1.0	65
382	Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clinical and Experimental Rheumatology, 2009, 27, 890-1.	0.4	12
383	Atypical Juvenile Polymyositis. Journal of Clinical Rheumatology, 2008, 14, 309-310.	0.5	3
384	Efficacy of Alendronate in the Treatment of the SAPHO Syndrome. Journal of Clinical Rheumatology, 2008, 14, 183-184.	0.5	19
385	Sulfasalazine-induced immune thrombocytopenia. Postgraduate Medical Journal, 2007, 83, e1-e1.	0.9	20
386	Therapeutic effect of spa therapy and short wave therapy in knee osteoarthritis: a randomized, single blind, controlled trial. Rheumatology International, 2007, 27, 523-529.	1.5	62
387	Erratum to â€œEffect of hyaluronic acid (MW 500â€“730 kDa) on proteoglycan and nitric oxide production in human osteoarthritic chondrocyte cultures exposed to hydrostatic pressureâ€•[Osteoarthritis Cartilage 13 (2005) 688â€“696]. Osteoarthritis and Cartilage, 2006, 14, 504-505.	0.6	0
388	Effect of hyaluronic acid (MW 500â€“730kDa) on proteoglycan and nitric oxide production in human osteoarthritic chondrocyte cultures exposed to hydrostatic pressure. Osteoarthritis and Cartilage, 2005, 13, 688-696.	0.6	33
389	Methods Used to Assess Clinical Outcome and Quality of Life in Osteoarthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 70-72.	1.6	2
390	Efficacy of intravenous neridronate in transient osteoporosis of the hip. Clinical and Experimental Rheumatology, 0, , .	0.4	0
391	Adalimumab for refractory idiopathic scleritis in children. Clinical and Experimental Rheumatology, 0, , .	0.4	2
392	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, , .	0.4	3
393	Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies. Rheumatology, 0, , .	0.9	0
394	Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases. Frontiers in Medicine, 0, 9, .	1.2	4
395	Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome. Frontiers in Medicine, 0, 9, .	1.2	10